imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
br-102 plus
schiller ag - registratori holter della pressione sanguigna
shin nippon br 7
towa medical instruments co. ltd. - apparecchiature per valutazione funzionale visiva
br�nemark syst mk iii groovy np 3.3x10mm
nobel biocare ab - impianti dentali
br�nemark syst mk iii groovy np 3.3x13mm
nobel biocare ab - impianti dentali
br�nemark syst mk iii groovy np 3.3x15mm
nobel biocare ab - impianti dentali
br�nemark syst mk iii groovy rp 4x11.5mm
nobel biocare ab - impianti dentali
br�nemark syst mk iii groovy wp 5x11.5mm
nobel biocare ab - impianti dentali
br�nemark syst mkiii groovy np3.3x11.5mm
nobel biocare ab - impianti dentali
br�nemark syst mkiii groovy rp 3.75x10mm
nobel biocare ab - impianti dentali